Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125718211 | 12571821 | 1 | I | 20160105 | 20160713 | 20160719 | 20160719 | PER | US-CELGENEUS-USA-2016073768 | CELGENE | 76.35 | YR | Y | 0.00000 | 20160719 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125718211 | 12571821 | 1 | PS | THALOMID | THALIDOMIDE | 1 | Oral | 200 MILLIGRAM | U | U | 20785 | 200 | MG | CAPSULES | QD | ||||
| 125718211 | 12571821 | 2 | SS | Daratumumab | DARATUMUMAB | 1 | Intravenous drip | U | U | 127058 | 16 | MG/KG | INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125718211 | 12571821 | 1 | Plasma cell myeloma |
| 125718211 | 12571821 | 2 | Plasma cell myeloma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125718211 | 12571821 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125718211 | 12571821 | Pneumonia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125718211 | 12571821 | 1 | 20150615 | 20150619 | 0 | |
| 125718211 | 12571821 | 2 | 20151208 | 20160127 | 0 |